- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Bristol
Headquarters: Bristol, United Kingdom
Website: http://www.bristol.ac.uk
Year Founded: 1876
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 28, 2025
Emerging Company Profile
Isomab: Rebalancing VEGF-A isoforms to promote blood vessel formation
University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head
BioCentury | Oct 23, 2024
Discovery & Translation
Science Spotlight: Novo’s glucose-sensing insulin, two bacterial immunotherapies, and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 3, 2024
Deals
Biotechs find problem-solving in academia, and mostly outside the big hubs
Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Jun 13, 2024
Discovery & Translation
Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 22, 2024
Emerging Company Profile
Purespring: treating kidney diseases via podocyte gene therapy platform
From monogenic targets to factories for local protein production, Purespring views podocytes as key to a range of kidney diseases
BioCentury | Aug 11, 2023
Discovery & Translation
Bacteria to detect tumors; plus Netris’ mAb to block EMT in cancer and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 14, 2021
Finance
July 14 Quick Takes: Patient Square Capital leads Kriya’s $100M B round; plus Entos, Ribon and more
Patient Square Capital led a $100 million series B round for Kriya Therapeutics Inc. to advance a pipeline of gene therapies for patients with prevalent and severe chronic diseases. New investors
BioCentury | Nov 19, 2020
Finance
Syncona enters kidney disease space with gene therapy newco Purespring
Firm launches sixth gene therapy start-up with £45M to reach clinic
BioCentury | Nov 6, 2020
Targets & Mechanisms
Data Byte: newly identified host factors that regulate ACE2 expression
Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies. ACE2 and TMPRSS2 are the most common host targets
BioCentury | Oct 14, 2019
Financial News
Mogrify raises $16M, outlines plans to advance cell therapy platform
Items per page:
1 - 10 of 42